ADAG Adagene Inc.

Price Chart

Executive Summary

Adagene announced updated Phase 1b/2 data for muzastotug in advanced MSS CRC, showing a 31% confirmed ORR at 20 mg/kg—more than double the 13% ORR at 10 mg/kg—along with improved PFS (6.7 vs 4.8 months) and durable responses. The FDA has granted Fast Track designation, and a randomized Phase 2 trial is ongoing with results expected in 1H 2027.

Actionable Insight

Key Facts

• Muzastotug achieved 31% confirmed ORR in 20 mg/kg cohorts vs 13% at 10 mg/kg in MSS CRC patients without liver metastases
• Median PFS improved to 6.7 months at 20 mg/kg vs 4.8 months at 10 mg/kg; mDOR not reached in 20 mg/kg cohorts
• Median OS not yet reached in 20 mg/kg cohorts; 1-year OS rate of 80.8% vs 70.1% at 10 mg/kg
• Low discontinuation rate (4%), no Grade 4/5 TRAEs; Grade 3 TRAEs manageable at 38% in 20 mg/kg cohorts
• FDA granted Fast Track designation for muzastotug + pembrolizumab in MSS mCRC without liver mets
• Randomized Phase 2 trial ongoing with data readout expected in 1H 2027

Financial Impact

Potential for significant value inflection upon Phase 2 readout; current market cap of $217M may not reflect full optionality of a differentiated CTLA-4 therapy

Risk Factors

• Phase 2 trial may not confirm Phase 1b/2 results, particularly in randomized setting
• Higher Grade 3 TRAEs at 20 mg/kg (38%) could limit dosing in broader populations
• Competitive landscape includes other CTLA-4 and combination immunotherapies in CRC

Market Snapshot

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

US Market Status

Related Tickers